Amneal Pharmaceuticals (AMRX) Depreciation & Amortization (CF) (2017 - 2026)

Amneal Pharmaceuticals' Depreciation & Amortization (CF) history runs 10 years deep, the most recent figure standing at $43.2 million for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) fell 28.21% year-over-year to $43.2 million; the TTM figure through Mar 2026 stood at $206.6 million (down 14.21% YoY), while the FY2025 annual figure was $223.6 million, down 5.34% from the prior year.
• Depreciation & Amortization (CF) was $43.2 million for Q1 2026 at Amneal Pharmaceuticals, down from $49.2 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $66.1 million in Q4 2024 to a low of $43.2 million in Q1 2026.
• Historically, Depreciation & Amortization (CF) has averaged $57.2 million across 5 years, with a median of $57.8 million in 2022.
• The sharpest annual moves came in 2024 and 2026: Depreciation & Amortization (CF) gained 16.15% in 2024, then declined 28.21% in 2026.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $61.1 million in 2022, then decreased by 6.75% to $56.9 million in 2023, then gained by 16.15% to $66.1 million in 2024, then retreated by 25.56% to $49.2 million in 2025, then dropped by 12.26% to $43.2 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $43.2 million (Q1 2026), $49.2 million (Q4 2025), and $54.1 million (Q3 2025), per Business Quant data.